Anti-Cancer Vaccine Gains Ground in China, Market May Exceed USD4.5 Billion
Liao Shumin
DATE:  Dec 19 2017
/ SOURCE:  Yicai
Anti-Cancer Vaccine Gains Ground in China, Market May Exceed USD4.5 Billion Anti-Cancer Vaccine Gains Ground in China, Market May Exceed USD4.5 Billion

(Yicai Global) Dec. 19 -- Human Papillomavirus Quadrivalent Vaccine will flow to medical institutions in Shanghai by next spring or later. The vaccine has won the bidding in 12 provinces, regions and central cities and its market scale is set to reach CNY30 billion (USD4.5 billion), cnstock.com reported.

The HPV quadrivalent vaccine prevents cancer of the cervix and anus, among other types, as well as genital warts. It works with both males and females. It has been very well-received by officialdom since hitting the market, winning the bidding in the provinces of Yunnan, Henan, Heilongjiang, Jiangxi, Hubei, Hunan, Sichuan, Fujian and Liaoning, the autonomous regions of Guangxi and Ningxia, and the centrally-administered megacity of Chongqing.

Shanghai's Municipal Center for Disease Control and Prevention has now completed its assessment of the HPV vaccine, formulated an inoculation schedule for it, and added it to the catalog of qualified second-category vaccines after conducting a suitability assessment and selection. The vaccine will be available to medical institutions in Shanghai by next spring or after.

China has 270 million females aged 20 to 45 and if 5 percent are vaccinated and the vaccine sells at CNY2,400 per three doses, the market size may reach CNY32 billion for women alone, a report by Zhongtai Securities Research Report concludes. Merck & Co. [NYSE:MRK], based in Kenilworth in the US state of New Jersey, produces the vaccine, which it markets under the Gardasil brand.

Follow Yicai Global on
Keywords:   HPV Vaccine